^
Association details:
Biomarker:TP53 mutation + TSC2 mutation
Cancer:Glioblastoma
Drug:everolimus (mTOR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

Successful treatment of a TSC2-mutant glioblastoma with everolimus

Excerpt:
A 14-year-old boy with...diagnosis of a gigantocellular-type glioblastoma multiforme (GBM)...As such, we performed whole exome and transcriptome sequencing, which revealed germline TP53 and somatic TSC2 mutations. On completion of adjuvant radiotherapy, he was started on maintenance therapy with everolimus per recommendations from our multi-institutional brain tumour precision medicine tumour board. He has achieved a complete remission with resolution of visual symptoms and remains on everolimus therapy with concurrent electromagnetic field therapy, now 33 months from diagnosis.
DOI:
10.1136/bcr-2018-227734